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Coronary artery diseaseThis month’s commentary focuses on familial hyperchole
sterolaemia (FH), a common genetic dyslipidaemia. If left un-
treated, FH markedly increases the risk of coronary heart disease
(CHD); at age 60 years, this risk is at least 50% in men and 30% in
women [1]. However, if diagnosed and appropriately treated, pa-
tients with heterozygous FH can have a normal life expectancy.
This scenario highlights two crucial needs: to diagnose FH early
and treat FH effectively. These have been the drivers for the most
recent Consensus Statement of the European Atherosclerosis Society
(EAS) [2], available to download at http://eurheartj.oxfordjournals.
org/content/early/2013/08/15/eurheartj.eht273.short?rss¼1.
The EAS believes that this timely Consensus Statement will
make a real difference to FH patients and save lives.
1. Scope of the problem: FH is underdiagnosed
Before the publication of this Consensus Statement, it was
generally accepted that about one in 500 people in the general
population have heterozygous FH, and one in a million have ho-
mozygous FH [3]. However, these values have been questioned as
they were derived from clinical data from over 30 years ago, using
less accurate methods.E-mail address: ofﬁce@eas-society.org.
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Study, an unselected North European general population sample,
highlight that these values markedly underestimate the prevalence
of FH. Based on the Dutch Lipid Clinic Network criteria for FH
(regarded as the gold standard), it was estimated that about one in
200 people had deﬁnite or probable FH [4]. These estimates
therefore suggest that up to 34 million people may be affected by
FH worldwide (Fig. 1).
However, it is clear that with few exceptions, the efﬁciency in
diagnosing FH lags far behind. In most countries, less than 1% of FH
patients are diagnosed [2]. The reasons for this are multiple, and
include the lack of valid nationwide registries for FH; lack of
screening strategies to detect index cases; and cost issues likely to
impact access to genetic testing. Importantly, there is a lack of
awareness of FH at the primary care. Clearly, there is a need for
urgent action to educate and improve diagnosis of FH.
2. Need to do better: EAS Consensus Panel recommendations
Addressing this issue, the EAS Consensus Panel has had made
a number of recommendations to improve screening for FH
(Table 1) [2].
The EAS Consensus Panel recommends cascade screening of
family members of known FH cases based on measurement of
plasma levels of low-density lipoprotein (LDL) cholesterol as the
most cost-effective screening method for identifying new FH sub-
jects. Index cases can be identiﬁed by opportunistic or targeted
screening in primary care or in hospital settings. Ideally, screening
should be systematic, centrally co-ordinated by a specialised centre
and based on both plasma lipid proﬁles and genetic testing. How-
ever, if genetic testing is not available, this can be based on the
plasma lipid proﬁle alone.
The Panel recommends the use of the Dutch Lipid Clinic
Network Criteria in adults to establish the clinical diagnosis of FH in
adults (Table 2). In individuals with deﬁnite/probable FH
(score > 5), genetic testing is recommended.
The Dutch Lipid Clinic Network Criteria are not appropriate in
children. For children, the optimal age for screening is between 2
and 10 years. Evidence of hypercholesterolaemia (total or LDL
cholesterol) on repeat testing after 2e3 months on dietary inter-
vention, should be a driver for further testing. In children with a
Fig. 1. Estimated frequency of heterozygous FH, based on prevalence rates of 1/500
and 1/200. Adapted from Nordestgaard et al. (2013) [2].
Table 2
Dutch Lipid Clinic Network criteria for diagnosis of FH in adults.
Points
Group 1 family history
First degree relative with
 Known premature CHD (<55 years in men,
<60 years in women)
1
OR
 Known LDL cholesterol >95th percentile by age
and gender for country
1
 Tendon xanthoma and/or corneal arcus 2
OR
 Children <18 years with LDL cholesterol >95th percentile by
age and gender for country
2
Group 2 Clinical history
Subject with
 Premature CHD (as deﬁned above) 2
 Premature cerebral or peripheral vascular disease
(as deﬁned above)
1
Group 3 Clinical examination
 Tendon xanthoma 6
 Corneal arcus in a person <45 years 4
Group 4 Biochemistry (LDL cholesterol)
 >8.5 mmol/L (>325 mg/dL) 8
 6.5e8.5 mmol/L (251e325 mg/dL) 5
 5.0e6.4 mmol/L (191e250 mg/dL) 3
 4.0e4.9 mmol/L (155e190 mg/dL) 1
Group 5 Molecular genetic testing
 Causative mutation in the LDLR, APOB, or PCSK9 genes 8
The highest single score in each group is considered.
Score > 8 deﬁnite FH; 6e8 probable FH; 3e5 possible FH; 0e2 unlikely FH.
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strongly suggestive of FH. Genetic testing is recommended in all
children of FH parents.
Genetic testing is now available in many countries for mutations
in the LDLR, APOB, PCSK9 and LDLRAP genes that are causative for FH
[5]. However, the EAS Consensus Panel recognises that despite
improved understanding the genetic causes of FH, no causal mu-
tation is detected in a proportion (10e40%) of patients with clinical
FH [6,7]. It may be that other key genes are implicated, or that there
are multiple small-effect genes (i.e. polygenic causality) that
contribute to increased LDL cholesterol. Irrespective of a genetic
diagnosis, all subjects with a clinical diagnosis of FH (see Table 2)
should be treated with an effective LDL cholesterol lowering agent.
For both adults and children, it is also important that secondary
causes of hypercholesterolaemia are excluded by checking liver,
renal and thyroid function and conﬁrming that there is no evidence
of hyperglycaemia or albuminuria.3. FH is undertreated
As highlighted by the EAS Consensus Panel, the severity of
atherosclerosis and coronary disease in FH is proportional to the
cumulative burden of elevated LDL cholesterol l levels. Studies have
shown that an LDL cholesterol burden sufﬁcient to cause CHD de-
velops at least 20 years earlier in untreated FH patients. For
example, the cumulative LDL burden at age 35 years in untreated
patients with heterozygous FH is similar to that in a 55-year oldTable 1
EAS Consensus Panel recommendations: who to screen for FH.
The EAS Consensus Panel recommends that children, adults and families should
be screened for FH if the following apply:
 A family member has FH
For individuals or family members:
 For adults, plasma cholesterol  8.0 mmol/L (310 mg/dL)a
 For children, plasma cholesterol  6.0 mmol/L (230 mg/dL)a
 Premature CHD
 Tendon xanthomas
 Sudden premature coronary death in a family member (<55 years in men
and <60 years in women)
a Or >95th percentile by age and gender for country in the individual or family
member.individual without FH [2,8,9]. However, if effective treatment is
instituted from an early age and LDL cholesterol targets are met
(see Table 3), this burden can be substantially reduced.
These data clearly highlight the critical importance of effective
treatment of FH to reduce the LDL cholesterol burden and risk for
atherosclerosis and CHD.
However, undertreatment of FH is a major issue. Less than <5%
of patients achieve the recommended LDL cholesterol targets. In
suboptimally treated patients with FH, coronary risk may be up to
13-fold higher than in those who attain recommended LDL
cholesterol targets [4].
4. Need to do better: EAS Consensus Panel recommendations
The EAS Consensus Panel recommends that patients with FH
should be initiated on maximal doses of potent statins at ﬁrst
consultation (Table 4) [2,10]. However, as it is likely that many of
these patients will not attain LDL cholesterol targets on statin
monotherapy, additional therapy will be required.
The EAS Consensus Panel [2] recommends the use of statin-
ezetimibe combination therapy in these patients, which is effec-
tive in reducing LDL cholesterol levels by 60e70%. For very high risk
FH patients with CHD or diabetes, the addition of a bile acid-
binding resin is recommended. Addition of a ﬁbrate (fenoﬁbrate)
to maximal statin dose may be considered in FH patients with
elevated triglycerides and low HDL cholesterol [2,11].
The EAS Consensus Panel recommends that most patients with
heterozygous FH bemanaged in primary care, preferably in a familyTable 3
Recommended LDL cholesterol targets for FH patients: EAS Consensus Panel and
Joint ESC/EAS guidelines [2,10].
 Children: < 3.5 mmol/L (<135 mg/dL)
 Adults: < 2.5 mmol/L (<100 mg/dL)
 Adults with CHD or diabetes < 1.8 mmol/L (<70 mg/dL)
Targets are the same in heterozygous and homozygous FH.
Table 4
EAS Consensus Panel recommendations for treatment priorities for FH [2].
Children
 Consider starting treatment at 8e10 years, in addition to lifestyle
management
 Treatment priorities: statin, ezetimibe, bile acid-binding resin. Only those
statins shown to be safe in children should be prescribed.
 Lipoprotein apheresis in children with homozygous FH.
Adults
 Start treatment on diagnosis, in addition to lifestyle management
 Treatment priorities: maximal potent statin dosea, ezetimibe, bile acid-
binding resin
 Lipoprotein apheresis in homozygous FH and treatment-resistant
heterozygous FH with CHD
a Maximal potent statin dose could be either atorvastatin 80 mg, rosuvastatin
40 mg, or pitavastatin 4 mg. Simvastatin 80 mg should not be used due to the po-
tential increased risk of myopathy.
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cialised lipid or FH clinics may also be useful.
However, the Panel recognises that some FH patients will
require specialist management, notably i) patients with statin
intolerance; ii) patients with CHD at very high cardiovascular risk
and iii) patients with very high LDL cholesterol levels despite
treatment (including those with homozygous FH). The latter two
patient categories may be considered for adjunctive lipoprotein
apheresis at specialised centres [12].
5. New focus on FH: novel therapies
FH has attracted renewed focus with the development of novel
therapies that are effective in lowering LDL cholesterol by 60% or
more. Such agents include:
 Therapeutic strategies targeting proprotein convertase subtil-
isin/kexin type 9 (PCSK9), including monoclonal antibody
therapies. Other treatments including siRNA, vaccines and
small molecule therapeutics targeting PCSK9 are at an earlier
stage of development.
 Antisense oligonucleotides targeting apolipoprotein B (such as
mipomersen) and
 Microsomal triglyceride transfer protein inhibitors (such as
lomitapide).The recent approval of mipomersen and lomitapide as adjunc-
tive therapy in the setting of homozygous FH has been regarded as a
‘new dawn’ for this serious, rare condition.
However, the impact of the EAS Consensus Panel Recommen-
dations and advent of novel therapies targeting LDL will be greatest
in the very much larger group of patients with heterozygous FH.
The EAS believes that this Consensus Statement on FHwill act as
a driver to raise awareness of FH in primary care, where earlier
diagnosis and effective treatment can markedly improve life ex-
pectancy among FH patients.
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